التفاصيل البيبلوغرافية
| العنوان: |
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging. |
| المؤلفون: |
Lietzau, Grazyna1 (AUTHOR) grazyna.lietzau@ki.se, Magni, Giulia2 (AUTHOR), Kehr, Jan3,4 (AUTHOR), Yoshitake, Takashi4 (AUTHOR), Candeias, Emanuel5 (AUTHOR), Duarte, Ana I.5 (AUTHOR), Pettersson, Hans1 (AUTHOR), Skogsberg, Josefin6 (AUTHOR), Abbracchio, Maria P.2 (AUTHOR), Klein, Thomas7 (AUTHOR), Nyström, Thomas1 (AUTHOR), Ceruti, Stefania2 (AUTHOR), Darsalia, Vladimer1 (AUTHOR) vladimer.darsalia@ki.se, Patrone, Cesare1 (AUTHOR) cesare.patrone@ki.se |
| المصدر: |
Neurobiology of Aging. May2020, Vol. 89, p12-23. 12p. |
| مصطلحات موضوعية: |
*HIGH performance liquid chromatography, *TYPE 2 diabetes, *DOPAMINE, *PARKINSON'S disease, *SULFONYLUREAS, *HIGH-fat diet |
| مستخلص: |
The nigrostriatal dopaminergic system (NDS) controls motor activity, and its impairment during type 2 diabetes (T2D) progression could increase Parkinson's disease risk in diabetics. If so, whether glycemia regulation prevents this impairment needs to be addressed. We investigated whether T2D impairs the NDS and whether dipeptidyl peptidase-4 inhibition (DPP-4i; a clinical strategy against T2D but also neuroprotective in animal models) prevents this effect, in middle-aged mice. Neither T2D (induced by 12 months of high-fat diet) nor aging (14 months) changed striatal dopamine content assessed by high-performance liquid chromatography. However, T2D reduced basal and amphetamine-stimulated striatal extracellular dopamine, assessed by microdialysis. Both the DPP-4i linagliptin and the sulfonylurea glimepiride (an antidiabetic comparator unrelated to DPP-4i) counteracted these effects. The functional T2D-induced effects did not correlate with NDS neuronal/glial alterations. However, aging itself affected striatal neurons/glia, and the glia effects were counteracted mainly by DPP-4i. These findings show NDS functional pathophysiology in T2D and suggest the preventive use of two unrelated anti-T2D drugs. Moreover, DPP-4i counteracted striatal age-related glial alterations suggesting striatal rejuvenation properties. • Type 2 diabetes (T2D) impairs release of dopamine in striatum during aging. • The DPP-4 inhibitor linagliptin and sulfonylurea glimepiride prevent this effect. • Aging but not T2D induces neuronal and glial alterations in striatum. • The effects on glia are partially but more selectively reduced by DPP-4 inhibition. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
